<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25011">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839214</url>
  </required_header>
  <id_info>
    <org_study_id>VB-201-064</org_study_id>
    <nct_id>NCT01839214</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis</brief_title>
  <acronym>MUC</acronym>
  <official_title>A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Biogenics Ltd. operating as VBL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Biogenics Ltd. operating as VBL Therapeutics</source>
  <oversight_info>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Bulgaria: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and efficacy in subjects with mild to moderate ulcerative
      colitis, as measured by Modified Mayo Score, Modified Baron Score, IBDQ, calprotectin and
      other assessments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Modified Mayo Score indicating remission</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of subjects in remission at Weeks 12 and 24 in the VB-201 160mg (80 mg BID) treatment group compared to placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Mayo Score indicating response</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of subjects responding at Weeks 12 and 24 in the VB-201 160mg (80 mg BID) treatment group compared to placebo group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>From Baseline through safety follow up at Week 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>As measured by changes from baseline in physical exam, vital signs, ECG, concomitant medications, laboratory values.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in Modified Mayo Score</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of subjects in each arm with a 2-point or greater decrease in the Modified Mayo score at Weeks 12 and 24.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Baron Score</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the modified Baron score from Baseline to Weeks 12 and 24 in the VB-201 treatment group as compared to the placebo group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mucosal Healing</measure>
    <time_frame>Wee 12 and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of subjects in each arm with mucosal healing at Weeks 12 and 24 in the VB-201 treatment group compared to placebo group.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>VB-201 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will received 80mg twice daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with crossover to VB-201 160mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects on placebo will crossover to VB-201 160 at week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB-201 160mg</intervention_name>
    <arm_group_label>VB-201 160mg</arm_group_label>
    <arm_group_label>Placebo with crossover to VB-201 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo with crossover to VB-201 160mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, ≥18 years of age, who has a diagnosis of active UC for at least 6
             months prior to screening

          -  A rectal/colonic biopsy obtained previously and consistent with a diagnosis of UC

          -  Endoscopy (flexible sigmoidoscopy unless surveillance colonoscopy is clinically
             indicated) confirming diagnosis of UC within 2 weeks prior to randomization

          -  Endoscopy (flexible sigmoidoscopy unless surveillance colonoscopy is clinically
             indicated) confirming diagnosis of UC within 2 weeks prior to randomization

          -  Active UC despite previous treatment with at least one 5-ASA compound at a dose of
             ≥2000 mg/day for at least 4 weeks or documented intolerance to such therapy

        Exclusion Criteria:

          -  Diagnosis of indeterminate colitis, Crohn's disease, or clinical findings suggestive
             of Crohn's disease (fistula or granulomas on biopsy) or microscopic colitis
             (collagenous colitis or lymphocytic colitis)

          -  Subject whose symptoms are likely caused by factors other than inflammatory UC,
             including infection or irritable bowel syndrome (IBS)

          -  History of dysplasia on colonic biopsy

          -  Subject with ≥ 8 year history of pancolitis or ≥ 15 year history of left sided
             colitis unless a colonoscopy with surveillance biopsies to screen for colon cancer
             has been performed within the past year

          -  Subject ≥ 50 years of age who has not had a colonoscopy to screen for colorectal
             polyps and colon cancer within the past 5 years

          -  Subject who has had any prior surgical resection of any part of the colon excluding
             the appendix

          -  Previous treatment with any biologic product including investigational biologic
             products

          -  The subject is taking Systemic corticosteroids,
             Azathioprine/6-mercaptopurine/methotrexate, immunosuppressants, Oral 5-ASA compounds
             unless they have been on a stable dose of sufficient duration prior to Baseline. If
             recently discontinued the subject must have had a wash-out periods of sufficient
             duration prior to Baseline

          -  Rectally administered corticosteroids or 5-ASA, antibiotics for the treatment of UC
             and probiotics within 14 days of the Baseline Visit and throughout the study

          -  The subject has with a stool culture positive for pathogenic ova or parasites,
             enteric pathogens or Clostridium difficile toxin at the Screening Visit

          -  Presence of, or history of cancer, with the exception of skin cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yael Cohen, MD</last_name>
    <phone>+972-3-634-6450</phone>
    <email>yaelc@vblrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VBL Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>April 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
